Provectus Biopharmaceuticals Inc.’ PV-10 Clinical Data On The Treatment Of Melanoma To Be Presented At European Society For Medical Oncology 2014 Congress
7/23/2014 12:08:35 PM
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT:PVCT) (www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (the "Company" or "Provectus"), will have clinical data on PV-10 presented at the European Society for Medical Oncology’s 2014 Congress in Madrid, Spain.
Help employers find you! Check out all the jobs and post your resume.
comments powered by